title: Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type.
abstract: The purposes of this study are to evaluate prognosis in patients with locoregionally recurrent extranodal nasal-type NK/T cell lymphoma (NKTCL) and to determine the value of salvage radiotherapy. Forty-two patients with NKTCL who developed first locoregional recurrence with (n = 13) or without (n = 29) systemic failure were reviewed. Retreatment included chemotherapy (n = 20), radiotherapy (n = 13), and radiotherapy plus chemotherapy (n = 9). Fifteen patients were reirradiated for localized recurrent disease. The 5-year overall survival (OS) rate after recurrence was 40 %, with a median survival of 26 months. The 2-year OS rate and median OS were 68 % and 36 months for locoregional recurrence only, compared with 31 % and 14 months for both locoregional and systemic recurrence, respectively (p = 0.034). Subgroup analysis for patients with localized recurrent disease revealed an improved OS with radiotherapy. The 2-year and 5-year OS rates were 77 and 69 % for radiotherapy, respectively, compared with a 2-year OS rate of 50 % and median OS of 16 months for chemotherapy alone (p = 0.006). Patients with localized recurrence had a better prognosis than those with systemic recurrence. Salvage radiotherapy or reirradiation resulted in a favorable prognosis for patients with localized recurrent disease.
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, 100021, People's Republic of China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhao
authors.forename: Ye-Xiong
authors.initials: YX
authors.lastname: Li
authors.forename: Shu-Lian
authors.initials: SL
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Jin
authors.forename: Wei-Hu
authors.initials: WH
authors.lastname: Wang
authors.forename: Yong-Wen
authors.initials: YW
authors.lastname: Song
authors.forename: Yue-Ping
authors.initials: YP
authors.lastname: Liu
authors.forename: Xin-Fan
authors.initials: XF
authors.lastname: Liu
authors.forename: Hui
authors.initials: H
authors.lastname: Fang
authors.forename: Hua
authors.initials: H
authors.lastname: Ren
authors.forename: Bo
authors.initials: B
authors.lastname: Chen
authors.forename: Shu-Nan
authors.initials: SN
authors.lastname: Qi
authors.forename: Qing-Feng
authors.initials: QF
authors.lastname: Liu
authors.forename: Ning-Ning
authors.initials: NN
authors.lastname: Lu
authors.forename: Zi-Hao
authors.initials: ZH
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis / Q000401:mortality* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000401:mortality* / Q000532:radiotherapy*; D009669:Nose Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy; D016879:Salvage Therapy / Q000379:methods* / Q000639:trends; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D055815:Young Adult